Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie

Juan Pablo Appendino; Cyrus Boelman; Paula M. Brna; Jorge G. Burneo; Curtis S. Claassen; Mary B. Connolly; Michael V.T. De Guzman; Paolo Federico; Deirdre Floyd; Richard James Huntsman; Manouchehr Javidan; Nathalie Jette; Laura L. Jurasek; Mark R. Keezer; Jonathan C. Lau; Bláthnaid McCoy; Richard S. McLachlan; Marcus C. Ng; Dang Khoa Nguyen; Aylin Y. Reid; Jong M. Rho; O. Carter Snead; José F. Téllez-Zenteno; Laura Wang; Maria Martha Zak

doi:10.1017/cjn.2019.282

Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie

Juan Pablo Appendino, Cyrus Boelman, Paula M. Brna, Jorge G. Burneo, Curtis S. Claassen, Mary B. Connolly, Michael V.T. De Guzman, Paolo Federico, Deirdre Floyd, Richard James Huntsman, Manouchehr Javidan, Nathalie Jette, Laura L. Jurasek, Mark R. Keezer, Jonathan C. Lau, Bláthnaid McCoy, Richard S. McLachlan, Marcus C. Ng, Dang Khoa Nguyen, Aylin Y. ReidJong M. Rho, O. Carter Snead, José F. Téllez-Zenteno, Laura Wang, Maria Martha Zak

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

9 Citas (Scopus)

Resumen

In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.

Título traducido de la contribución	Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada
Idioma original	French
Páginas (desde-hasta)	645-652
Número de páginas	8
Publicación	Canadian Journal of Neurological Sciences
Volumen	46
N.º	6
DOI	https://doi.org/10.1017/cjn.2019.282
Estado	Published - nov. 1 2019

Nota bibliográfica

Funding Information:
Dr. Appendino has nothing to disclose. Dr. Boelman has nothing to disclose. Dr. Brna has nothing to disclose. Dr. Burneo reports supports for educational and research activities from Jack Cowin Chair in Epilepsy Research, from Eisai Canada, and from Sunovion Canada, outside the submitted work. RPh. Curtis Claassen has nothing to disclose. Dr. Connolly is a co-investigator for the Cannabidiol in Children with Refractory Epileptic Encephalopathy study. For this study, it is used Cannimed’s 1:20 THC-CBD Cannabis herbal extract. Dr. Connolly receives no financial support from Cannimed and purchases the product used in the study from Cannimed at the cost of production. She has nothing to disclose. RPh. De Guzman has nothing to disclose. Dr. Federico has nothing to disclose. Mrs. Floyd has nothing to disclose. Dr. Huntsman is the lead investigator for the Cannabidiol in Children with Refractory Epileptic Encephalopathy study. For this study, it is used Cannimed’s 1:20 THC-CBD Cannabis herbal extract. Dr. Hunstman received no financial support from Cannimed and purchased the product used in the study from them at the cost of production. Dr. Javidan has nothing to disclose. Dr. Jette received grant funding paid to her institution for grants unrelated to this work from NINDS (NIH U24NS107201, NIH IU54NS100064), PCORI, and Alberta Health. She also received an honorarium for her work as an associate editor of Epilepsia . NP. Jurasek has nothing to disclose. Dr. Keezer reports personal fees from Elsevier, personal fees from Sunovion, personal fees from Novartis, personal fees from Sage Therapeutics, grants and personal fees from UCB, grants and personal fees from Eisai, outside the submitted work. Dr. Lau has nothing to disclose. Dr. McCoy is a PI in a study of cannabinoids in resistant epilepsy, which was part funded by study drug vendor. Dr. McLachlan has nothing to disclose. Dr. Ng has nothing to disclose. Dr. Nguyen reports grants and personal fees from UCB; personal fees from Sunovion and personal fees from Eisai outside the submitted work. Dr. Reid has nothing to disclose. Dr. Rho reports other from Dr. Robert Haslam Chair in Child Neurology, personal fees from UCB Pharma, personal fees from Danone Nutricia, personal fees from Accera Pharma, outside the submitted work. Dr. Snead , Dr. Tellez-Zenteno, and RPh. Wang have nothing to disclose. NP Maria Zak was a co-investigator of a CBD Study in Children with Dravet Syndrome in which the CBD was provided in kind by Tilray.

Publisher Copyright:
© 2019 The Canadian Journal of Neurological Sciences Inc.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

PubMed: MeSH publication types

Journal Article
Review

Acceder al documento

10.1017/cjn.2019.282

Otros archivos y enlaces

Citar esto

Appendino, J. P., Boelman, C., Brna, P. M., Burneo, J. G., Claassen, C. S., Connolly, M. B., De Guzman, M. V. T., Federico, P., Floyd, D., Huntsman, R. J., Javidan, M., Jette, N., Jurasek, L. L., Keezer, M. R., Lau, J. C., McCoy, B., McLachlan, R. S., Ng, M. C., Nguyen, D. K., ... Zak, M. M. (2019). Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie. Canadian Journal of Neurological Sciences, 46(6), 645-652. https://doi.org/10.1017/cjn.2019.282

Appendino, JP, Boelman, C, Brna, PM, Burneo, JG, Claassen, CS, Connolly, MB, De Guzman, MVT, Federico, P, Floyd, D, Huntsman, RJ, Javidan, M, Jette, N, Jurasek, LL, Keezer, MR, Lau, JC, McCoy, B, McLachlan, RS, Ng, MC, Nguyen, DK, Reid, AY, Rho, JM, Snead, OC, Téllez-Zenteno, JF, Wang, L & Zak, MM 2019, 'Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie', Canadian Journal of Neurological Sciences, vol. 46, n.º 6, pp. 645-652. https://doi.org/10.1017/cjn.2019.282

@article{12f4e7bbcacc4dffac4ff1524f6c4553,

title = "{\'E}nonc{\'e} de position quant {\`a} l'utilisation du cannabis m{\'e}dical dans le traitement de l'{\'e}pilepsie",

abstract = "In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.",

author = "Appendino, {Juan Pablo} and Cyrus Boelman and Brna, {Paula M.} and Burneo, {Jorge G.} and Claassen, {Curtis S.} and Connolly, {Mary B.} and {De Guzman}, {Michael V.T.} and Paolo Federico and Deirdre Floyd and Huntsman, {Richard James} and Manouchehr Javidan and Nathalie Jette and Jurasek, {Laura L.} and Keezer, {Mark R.} and Lau, {Jonathan C.} and Bl{\'a}thnaid McCoy and McLachlan, {Richard S.} and Ng, {Marcus C.} and Nguyen, {Dang Khoa} and Reid, {Aylin Y.} and Rho, {Jong M.} and Snead, {O. Carter} and T{\'e}llez-Zenteno, {Jos{\'e} F.} and Laura Wang and Zak, {Maria Martha}",

note = "Publisher Copyright: {\textcopyright} 2019 The Canadian Journal of Neurological Sciences Inc.",

year = "2019",

month = nov,

day = "1",

doi = "10.1017/cjn.2019.282",

language = "Fran{\c c}ais",

volume = "46",

pages = "645--652",

journal = "Canadian Journal of Neurological Sciences",

issn = "0317-1671",

publisher = "Canadian Journal of Neurological Sciences",

number = "6",

}

TY - JOUR

T1 - Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie

AU - Appendino, Juan Pablo

AU - Boelman, Cyrus

AU - Brna, Paula M.

AU - Burneo, Jorge G.

AU - Claassen, Curtis S.

AU - Connolly, Mary B.

AU - De Guzman, Michael V.T.

AU - Federico, Paolo

AU - Floyd, Deirdre

AU - Huntsman, Richard James

AU - Javidan, Manouchehr

AU - Jette, Nathalie

AU - Jurasek, Laura L.

AU - Keezer, Mark R.

AU - Lau, Jonathan C.

AU - McCoy, Bláthnaid

AU - McLachlan, Richard S.

AU - Ng, Marcus C.

AU - Nguyen, Dang Khoa

AU - Reid, Aylin Y.

AU - Rho, Jong M.

AU - Snead, O. Carter

AU - Téllez-Zenteno, José F.

AU - Wang, Laura

AU - Zak, Maria Martha

PY - 2019/11/1

Y1 - 2019/11/1

N2 - In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.

AB - In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.

UR - http://www.scopus.com/inward/record.url?scp=85074184984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074184984&partnerID=8YFLogxK

U2 - 10.1017/cjn.2019.282

DO - 10.1017/cjn.2019.282

M3 - Article de revue

C2 - 31466531

AN - SCOPUS:85074184984

SN - 0317-1671

VL - 46

SP - 645

EP - 652

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

IS - 6

ER -

Énoncé de position quant à l'utilisation du cannabis médical dans le traitement de l'épilepsie

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto